Why Robert Glaser Acquires 35,755 Shares of RealNetworks, Inc. (RNWK)?; Prothena PLC (PRTA) Has 1.18 Sentiment

Prothena Corporation plc (NASDAQ:PRTA) Logo

Sentiment for Prothena Corp PLC (PRTA)

Prothena Corp PLC (PRTA) investors sentiment decreased to 1.18 in Q4 2017. It’s down -0.47, from 1.65 in 2017Q3. The ratio turned negative, as 72 hedge funds opened new or increased equity positions, while 61 decreased and sold holdings in Prothena Corp PLC. The hedge funds in our database now own: 31.32 million shares, up from 31.24 million shares in 2017Q3. Also, the number of hedge funds holding Prothena Corp PLC in top ten equity positions decreased from 1 to 0 for a decrease of 1. Sold All: 29 Reduced: 32 Increased: 44 New Position: 28.

Investors sentiment increased to 1.42 in Q4 2017. Its up 0.22, from 1.2 in 2017Q3. It increased, as 2 investors sold RealNetworks, Inc. shares while 17 reduced holdings. 8 funds opened positions while 19 raised stakes. 19.60 million shares or 1.38% more from 19.34 million shares in 2017Q3 were reported. Tower Research Limited Liability Corp (Trc) holds 9,219 shares or 0% of its portfolio. Millennium Mgmt Llc invested in 0% or 85,075 shares. Morgan Stanley holds 47,304 shares or 0% of its portfolio. Ancora Advsr Ltd Liability Com holds 0.04% of its portfolio in RealNetworks, Inc. (NASDAQ:RNWK) for 230,377 shares. Schwab Charles Investment Mngmt has 0% invested in RealNetworks, Inc. (NASDAQ:RNWK) for 95,855 shares. Axa reported 0% in RealNetworks, Inc. (NASDAQ:RNWK). Rhumbline Advisers reported 27,692 shares. Blackrock owns 1.94M shares. Renaissance Technology Llc holds 0% or 1.16 million shares in its portfolio. Legal General Public Limited Company has 3,691 shares. Parametric Assoc Ltd Llc owns 32,447 shares or 0% of their US portfolio. Vanguard Grp holds 1.06 million shares or 0% of its portfolio. 2.43M are held by Dimensional Fund Advisors Lp. 3,953 are owned by Barclays Plc. Fuller Thaler Asset Management stated it has 0.01% in RealNetworks, Inc. (NASDAQ:RNWK).

RealNetworks, Inc. provides network-delivered digital media applications and services to manage, play, and share digital media. The company has market cap of $129.58 million. The firm operates through three divisions: Consumer Media, Mobile Services, and Games. It currently has negative earnings. The Consumer Media segment offers RealPlayer media player software, which enables clients to discover, play, download, manage and edit digital video, stream audio and video, download and save photos and videos from the Web, transfer and share content on social networks, and edit their own photo and video content.

The stock increased 0.29% or $0.01 during the last trading session, reaching $3.47. About 66,144 shares traded. RealNetworks, Inc. (NASDAQ:RNWK) has declined 30.26% since April 19, 2017 and is downtrending. It has underperformed by 41.81% the S&P500.

Robert Glaser; that is an insider in Realnetworks Inc who is the last to buy shares in the corporation for which he is right now a Chairman and CEO. He recently purchased 35,755 shares of the company, valued by the market at around $120,677 U.S. Dollars, that is a price for each share of approx. $3.4. In the last month, he also bought 46,509 shares that are worth approx $142,887 USD. This acquisition was reported on 18-04-2018 and is already filed with the U.S. Security and Exchange Commission. The public 4F filing is obtainable online to the public here. Robert Glaser currently has rights to 13.05 million shares or 34.95% of Realnetworks Inc’s market cap.

Since February 28, 2018, it had 4 insider buys, and 0 insider sales for $258,425 activity. On Wednesday, February 28 Baker Cary bought $104,989 worth of RealNetworks, Inc. (NASDAQ:RNWK) or 35,816 shares. $49,435 worth of stock was bought by GLASER ROBERT on Monday, April 9.

Ratings analysis reveals 100% of Prothena’s analysts are positive. Out of 3 Wall Street analysts rating Prothena, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $69.0 while the high is $86.0. The stock’s average target of $76.67 is 112.91% above today’s ($36.01) share price. PRTA was included in 3 notes of analysts from December 21, 2016. The stock of Prothena Corporation plc (NASDAQ:PRTA) earned “Overweight” rating by Piper Jaffray on Wednesday, April 12. The stock of Prothena Corporation plc (NASDAQ:PRTA) earned “Overweight” rating by Cantor Fitzgerald on Wednesday, April 12. SunTrust initiated Prothena Corporation plc (NASDAQ:PRTA) rating on Wednesday, December 21. SunTrust has “Buy” rating and $75.0 target.

Analysts await Prothena Corporation plc (NASDAQ:PRTA) to report earnings on May, 8. They expect $-1.24 earnings per share, down 25.25% or $0.25 from last year’s $-0.99 per share. After $-1.24 actual earnings per share reported by Prothena Corporation plc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Palo Alto Investors Llc holds 1.77% of its portfolio in Prothena Corporation plc for 1.10 million shares. Sphera Funds Management Ltd. owns 205,000 shares or 0.9% of their US portfolio. Moreover, Sectoral Asset Management Inc has 0.86% invested in the company for 184,063 shares. The Maryland-based Rock Springs Capital Management Lp has invested 0.53% in the stock. Hood River Capital Management Llc, a Oregon-based fund reported 213,119 shares.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The company has market cap of $1.39 billion. It is developing antibody product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating ParkinsonÂ’s disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. It currently has negative earnings. The firm has a license, development, and commercialization agreement with F.

RealNetworks, Inc. (NASDAQ:RNWK) Institutional Positions Chart